INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
There is substantial evidence from animal model and healthy control data, that oxytocin is
involved in the modulation of social cognition. In addition, recent genetics and plasma level
studies suggest a possible role for oxytocin in the pathophysiology of Autism Spectrum
Disorders (ASD). As a large number of children with ASD are transitioning into adulthood and
will likely require treatment, the lack of data to make meaningful treatment recommendations
to facilitate adult living is an urgent issue. This study will examine the effect of
intranasal oxytocin (IN-OXT) on social function in adults with ASD. It is hypothesized that
IN-OXT will be superior to placebo in improving social function by the end of study
treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Evdokia Anagnostou
Collaborators:
Holland Bloorview Kids Rehabilitation Hospital McMaster University St. Michael's Hospital, Toronto Unity Health Toronto